



Silere Medical Technology Press Release

April 7th, 2011

FOR IMMEDIATE RELEASE

Contact: Michael F. Langhout, President and CEO, Silere Medical Technology, Inc.

+1-425-269-3000

Michael Langhout Panelist at Washington Biotechnical Biomedical Association Leadership Summit

Bothell, Washington, April 7th, 2009 - Michael Langhout, President and CEO of Silere Medical Technology, Inc., a medical device company located in Kirkland, Washington, participated in a panel discussion at the Washington Biotechnology & Biomedical Association Annual Medical Device conference held in Bothell, Washington.

The conference, titled "A Leadership Summit: Leading with International Markets for Medical Technology Commercialization – Boom or Bust?", featured two keynote speakers, Beckie Robertson, a veteran medical device investor and managing director with Versant Ventures, a top tier medical device venture capital firm located in Menlo Park, CA., and Rob Michiels, President and CEO of CardiaQ in Irvine California, and the former president of CoreValve, an aortic valve device company acquired by Medtronic in 2009.

The Leadership Panel was moderated by Richard Shea; CEO of Redmond, WA based Spiration. Other panelists included Nancy Hill of Spiration, and John Bowers of Sonosite, based in Bothell, WA. Each of the panelists addressed difficulties medical device companies experience when seeking making pre market device authorization for device approvals with the FDA. The panel question and answer session with the two speakers was robust and informative.

The discussion focused on strategies for commercializing medical technologies outside the United States first in order to gain regulatory approvals, and keep costs under control.

Silere Medical is a medical device company developing an electrical neural prosthesis targeting suppression of chronic tinnitus. Regulatory strategy for the company includes clinical trials in European centers to obtain CE Mark, concurrent with feasibility and pivotal IDE studies in the United States.

This platform builds on the technology of neural pain suppression stimulators and the cochlear implant, the most sophisticated neural prosthetic currently in distribution. Much has been learned about this technology used in these devices over the past three decades which further reduces device and business

risk. Additionally, there has been significant development and refinement in the surgical methods used to implant these devices and the clinical techniques needed to fit them to patients.

“With this device, Silere will apply and refine the technology developed for and used in cochlear implants during the past decade. We will integrate our proprietary electrode technology and system design technology into system to provide a robust and highly functional product that provides the clinician a powerful flexible platform to treat tinnitus. The TheraStim 6000™, the first microelectronic Implantable Therapeutic Stimulator (ITS) designed to suppress chronic tinnitus.

About Silere Medical Technology

Based in Kirkland, WA, Silere Medical intends to design, fabricate, and market electrical neurostimulation devices treating disorders of the auditory processing system. The primary and initial focus is chronic tinnitus, a condition which can be debilitating for millions. Silere’s unique treatment method was developed at University of Iowa by Jay Rubinstein, MD, PhD, and internationally recognized thought leaders in disorders of the auditory processing system, cochlear implants, and tinnitus research.

Silere Medical was co-founded by industry veterans, including William ‘Van’ Harrison, Jay T. Rubinstein, MD., PhD, Michael Langhout, Dorcas Kessler, MA, and Chris Zobkiw. Silere Medical has been financed by its founders through to its demonstration of Proof of Concept in humans.